Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Talmapimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 14/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 2/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 1.00 |
| ▸ | ACTR2 | P61160 | 1/20 | 1.00 |
| ▸ | CCR1 | P32246 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Talmapimod SCHEMBL4779238 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| Talmapimod SCHEMBL2369829 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| Talmapimod SCHEMBL29437775 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| Talmapimod SCHEMBL14185104 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| Talmapimod SCHEMBL29394770 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| Talmapimod SCHEMBL14338006 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| Talmapimod SCHEMBL5649978 | 0.99 | MAPK14 (0.98) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL14587886 | 0.92 | MAPK14 (0.85) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL4512542 | 0.91 | MAPK14 (0.83) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL4503552 | 0.91 | MAPK14 (0.83) | MAPK14MAPK11MAPK13MAPK12NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 940 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| US-12370180-B2 | P38 map kinase inhibitors for treating Friedreich's ataxia | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-07-29 | — | — | US | claimed |
| EP-4587558-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | Fate Therapeutics, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| US-20250215397-A1 | TWO-DIMENSIONAL CULTURE METHOD HAVING CLEAR CHEMICAL COMPOSITION FOR CULTURING THREE-DIMENSIONAL INTESTINAL ORGANOID-DERIVED INTESTINAL STEM CELL AGGREGATE | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2025-07-03 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-119948152-A | Methods and compositions for inducing hematopoietic cell differentiation | 菲特治疗公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119698462-A | Two-dimensional culture method with definite chemical composition for culturing three-dimensional intestinal organoid derived intestinal stem cell population | 韩国生命工学研究院 | 2025-03-25 | — | — | CN | claimed |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | DBCC RES LLC (US) | 2024-09-26 | — | — | US | claimed |
| EP-4416268-A1 | METHODS FOR PRODUCING CARTILAGE AND BONES | Murdoch Children's Research Institute (AU) | 2024-08-21 | — | — | EP | claimed |
| CN-118355110-A | Method for producing cartilage and bone | 默多克儿童研究所 | 2024-07-16 | — | — | CN | claimed |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | SAINT LOUIS UNIVERSITY (US) | 2022-03-17 | — | — | US | claimed |
| US-11266700-B2 | Compositions and methods for treating immune disorders using immune modulating Lactococcus bacteria strains | EVELO BIOSCIENCES, INC. (US) | 2022-03-08 | — | — | US | claimed |
| WO-2022020364-A1 | PREVOTELLA HISTICOLA STRAIN C AS AN ORAL THERAPY FOR INFLAMMATORY DISEASES | EVELO BIOSCIENCES, INC. (US) | 2022-01-27 | — | — | WO | claimed |
| WO-2022020326-A1 | VEILLONELLA PARVULA STRAIN AS AN ORAL THERAPY FOR NEUROINFLAMMATORY DISEASES | EVELO BIOSCIENCES, INC. (US) | 2022-01-27 | — | — | WO | claimed |
| US-20180071376-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2018-03-15 | — | — | US | claimed |
| EP-3274053-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | The Brigham and Women's Hospital, Inc. (US) | 2018-01-31 | — | — | EP | claimed |
| US-9517241-B2 | Amelioration of intestinal fibrosis and treatment of Crohn's disease | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-12-13 | — | — | US | claimed |
| WO-2016154362-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-09-29 | — | — | WO | claimed |
| US-20160166587-A1 | AMELIORATION OF INTESTINAL FIBROSIS AND TREATMENT OF CROHN'S DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-06-16 | — | — | US | claimed |
| WO-2014122298-A1 | INTERLEUKIN-4 INHIBITORS FOR THE TREAMTENT OF NEUTROPENIA | Universität Zürich (CH) | 2014-08-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166587-A1 | AMELIORATION OF INTESTINAL FIBROSIS AND TREATMENT OF CROHN'S DISEASE | NOD2, NFKBIA, VIP | MAPK14 2171/4885MAPK11 1660/4885MAPK13 1208/4885 |
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | PBK, CD4, CD22 | MAPK14 1645/4885MAPK11 1894/4885MAPK13 902/4885 |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | BRDT, PHKB, BET1 | MAPK14 3891/4885MAPK11 2811/4885MAPK13 2734/4885 |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | ECHS1, GLS2, OAT | MAPK14 4665/4885MAPK11 4713/4885MAPK13 4620/4885 |
| US-20180071376-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | IAPP, NFATC1, CD4 | MAPK14 2820/4885MAPK11 2451/4885MAPK13 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.